KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: KX2-391 may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of KX2-391 in treating
patients with advanced solid tumors or lymphoma that did not respond to treatment.